Generics in France

Date: October 27, 2017
Pages: 35
Price:
US$ 350.00
License [?]:
Publisher: MarketLine
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: GD1EF4ABE3BEN
Leaflet:

Download PDF Leaflet

Generics in France
Generics in France

SUMMARY

Generics in France industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

SYNOPSIS

Essential resource for top-line data and analysis covering the France generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

KEY HIGHLIGHTS

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The market value is evaluated at ex-factory prices.
Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
Please note that any volumes of '1' (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
All currency conversions were calculated at constant average annual 2016 exchange rates.
The French generics market had total revenues of $3,850.1m in 2016, representing a compound annual growth rate (CAGR) of 2.1% between 2012 and 2016.
Market consumption volume increased with a CAGR of 7.9% between 2012 and 2016, to reach a total of 0.4 % in 2016.
The government is pushing for more generic use and this will drive the market growth and market consumption.

SCOPE
  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in France
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in France
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the France generics market with five year forecasts by both value and volume
REASONS TO BUY
  • What was the size of the France generics market by value in 2016?
  • What will be the size of the France generics market in 2021?
  • What factors are affecting the strength of competition in the France generics market?
  • How has the market performed over the last five years?
  • How large is France’s generics market in relation to its regional counterparts?


NOTE: Out of security concerns MarketLine requires using corporate email address.
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Novartis AG
Sanofi SA
Les Laboratoires Servier
Teva Pharmaceutical Industries Limited
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

LIST OF TABLES

Table 1: France generics market value: $ million, 2012-16
Table 2: France generics market volume: % of total pharma volume, 2012-16
Table 3: France generics market geography segmentation: $ million, 2016
Table 4: France generics market value forecast: $ million, 2016-21
Table 5: France generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Novartis AG: key facts
Table 7: Novartis AG: key financials ($)
Table 8: Novartis AG: key financial ratios
Table 9: Sanofi SA: key facts
Table 10: Sanofi SA: key financials ($)
Table 11: Sanofi SA: key financials (€)
Table 12: Sanofi SA: key financial ratios
Table 13: Les Laboratoires Servier: key facts
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: France size of population (million), 2012-16
Table 18: France gdp (constant 2005 prices, $ billion), 2012-16
Table 19: France gdp (current prices, $ billion), 2012-16
Table 20: France inflation, 2012-16
Table 21: France consumer price index (absolute), 2012-16
Table 22: France exchange rate, 2012-16

LIST OF FIGURES

Figure 1: France generics market value: $ million, 2012-16
Figure 2: France generics market volume: % of total pharma volume, 2012-16
Figure 3: France generics market geography segmentation: % share, by value, 2016
Figure 4: France generics market value forecast: $ million, 2016-21
Figure 5: France generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in France, 2016
Figure 7: Drivers of buyer power in the generics market in France, 2016
Figure 8: Drivers of supplier power in the generics market in France, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in France, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in France, 2016
Figure 11: Drivers of degree of rivalry in the generics market in France, 2016
Figure 12: Novartis AG: revenues & profitability
Figure 13: Novartis AG: assets & liabilities
Figure 14: Sanofi SA: revenues & profitability
Figure 15: Sanofi SA: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities

COMPANIES MENTIONED

Novartis AG
Sanofi SA
Les Laboratoires Servier
Teva Pharmaceutical Industries Limited
Skip to top


Generics Global Industry Guide 2017-2021 US$ 1,495.00 Feb, 2018 · 247 pages
Analyzing the Global Generics Industry 2017 US$ 1,000.00 Mar, 2017 · 440 pages
Europe Generic drug Market Report 2016 US$ 3,900.00 Nov, 2016 · 113 pages

Ask Your Question

Generics in France
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: